Register for our free email digests:
University of California, San Diego
Division of University of California
Latest From University of California, San Diego
Biomarkers for psychiatric disorders are lacking, but Astellas is investing in its own and external efforts to identify drug targets as well as patients who'll respond to new therapies.
As PD-1 inhibitors march toward earlier-stage head and neck cancers, researchers consider ways to improve the precision of immunotherapy through better patient selection and combinations for this accessible tumor type.
Emerging Company Profile: Firms that label themselves as microbiome companies have mushroomed in the past couple of years. Leading BioSciences likes to think it's working on "microbiome 2.0" and has filed a trademark application for the term "gastrobiome" to express that differentiation.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in January and February 2017.
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.